During the past decade, Universitäts-Augenklinik Tübingen conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Universitäts-Augenklinik Tübingen" are "Geographic Atrophy" (1 trials), "Macular Degeneration" (1 trials), "Non Arteritic Anterior Ischemic Optic Neuropathy" (1 trials), "Primary Open Angle Glaucoma (POAG)" (1 trials) and "Primary Open-angle Glaucoma" (1 trials). Many other conditions were trialed in "Universitäts-Augenklinik Tübingen" in a lesser frequency.

Most popular intervention types in "Universitäts-Augenklinik Tübingen" are "Device" (2 trials), "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "ARGOS-IO Sensor Pressure System" (1 trials), "ARGOS-IO system" (1 trials), "QPI-1007 Injection - 1.5 mg" (1 trials), "QPI-1007 Injection - 3.0 mg" (1 trials) and "Sham" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitäts-Augenklinik Tübingen" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Universitäts-Augenklinik Tübingen". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Universitäts-Augenklinik Tübingen, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Universitäts-Augenklinik Tübingen, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".